Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), recently announced a $90M investment plan to expand two of its U.S. facilities, which are critical to its integrated biconjugate development offering, ADCelerate™.
The Riverview, Michigan site provides comprehensive drug substance development and manufacturing services, including specialized solutions for high potency APIs (HPAPIs). Capabilities include the supply of payload-linkers essential to the overall safety, stability, and efficacy of ADC therapies. The expansion, which is expected to be operational in early 2026, will add a commercial-scale suite specifically designed for the development and manufacturing of payload-linkers.
The Lexington, Kentucky site is Piramal’s dedicated fill/finish facility, specializing in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. The expansion adds commercial-scale sterile injectable manufacturing capabilities with 24,000 s.f. of additional manufacturing space, a new laboratory, and state-of-the-art machinery, including a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer. The expansion is expected to be completed by late 2027.
This investment comes at a pivotal moment for the sterile injectables market, which is experiencing significant growth driven by increased medical necessity, broader regulatory approvals, and sizable advancements in scientific research and development. ADC therapies are being fueled by ongoing innovation, wider regulatory acceptance, and robust evidence demonstrating their effectiveness. The growing prevalence of ADCs underscores the pressing need for expanded manufacturing and development capabilities to meet the evolving landscape of patient care.
The expansions position Piramal Pharma to capitalize on these trends, ensuring the company can meet the rising demand for both sterile injectables and ADC therapies while enhancing its competitive edge in the market. Upon completion, the Lexington site will more than double its manufacturing capacity, increasing from 104 product batches per year (at peak utilization) to over 240 annual batches.
“As the market adjusts and preferences shift, we are committed to adapting to meet its current requirements,” said Peter DeYoung, Chief Executive Officer, Piramal Global Pharma. “ADCs are rapidly emerging as one of the most effective classes of precision immunotherapy targeting certain cancers and tumors. As this class of drugs becomes more prevalent, we will adapt our services to accommodate this growing demand. By investing in the Lexington and Riverview facilities, we will enhance our integrated ADC offering, ADCelerate™, and increase our capacity to bring high-quality, innovative treatments to our clients and their patients worldwide.”
For more information, email contact.us@piramal.com
